^
Association details:
| Biomarker: | KMT2C mutation |
|---|---|
| Cancer: | Solid Tumor |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumors
Excerpt:
...we validated the predictive potential of KMT2A/C mutations in an expanded ICI-treated cohort (n = 1395). KMT2A/C-mutant patients achieved better OS compared with KMT2A/C-wildtype patients (HR = 0.68, P = 0.003); and the survival advantages appeared in the majority of cancer subtypes.
DOI:
10.1186/s40364-020-00241-0
